A middle-aged man with well-controlled diabetes developed unexplained liver enzyme elevations while on semaglutide, which resolved after stopping the medication.
Rapid resolutionLiver enzyme levels declined quickly after semaglutide discontinuation, with no alternative cause identified
What the researchers found
A middle-aged male with well-controlled type 2 diabetes and social alcohol use developed asymptomatic elevations in ALT and AST while taking semaglutide. A comprehensive workup — including undetectable blood ethanol, normal viral hepatitis panel, and unremarkable liver ultrasound — found no alternative cause.
After semaglutide was discontinued, transaminase levels declined rapidly, supporting a diagnosis of drug-induced liver injury (DILI). The mechanism remains unclear but may involve idiosyncratic metabolic stress, weight loss effects, or biliary dysfunction.
Why it matters
As semaglutide use explodes for diabetes and weight loss, identifying rare adverse effects is critical for patient safety. This case reminds clinicians to monitor liver enzymes and consider semaglutide as a potential cause of unexplained liver injury, even though the drug is generally considered hepatoprotective.
How the study worked
This is a single case report. The patient underwent standard clinical workup including liver enzyme panels, blood ethanol level, viral hepatitis screening, and liver ultrasound. The temporal relationship between semaglutide use, enzyme elevation, drug discontinuation, and enzyme normalization was used to establish a likely causal link.
What this study cannot tell us
This is a single case report, the weakest form of clinical evidence. It cannot prove causation — only temporal association. The patient had social alcohol use, which could theoretically contribute despite undetectable ethanol at presentation. No liver biopsy was performed to confirm the mechanism, and no rechallenge was attempted.
How to read the evidence
This is a single case report, which represents the lowest level of clinical evidence. While it raises an important safety signal, it cannot establish causation or estimate the frequency of this adverse effect.
When this study was published
Published in 2025 in Clinical Case Reports, this is a very recent case reflecting the current era of widespread semaglutide prescribing.
The bigger picture
GLP-1 receptor agonists like semaglutide are being prescribed to millions of patients worldwide. While clinical trials have shown liver-protective effects overall, post-marketing surveillance and case reports like this one are essential for catching rare adverse events that trials may not have been large enough to detect.
Questions still open
- How common is idiosyncratic liver injury with semaglutide, and should routine liver monitoring be recommended?
- Could dose adjustments (rather than discontinuation) have been sufficient to resolve the liver enzyme elevations?
- Is there a genetic predisposition that makes certain patients vulnerable to GLP-1 agonist-related liver injury?
Common questions
Should I be worried about liver damage from semaglutide?
What is drug-induced liver injury (DILI)?
Read the original research
Semaglutide-Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury.
Clinical case reports, 13(8), e70783
Citation
Kundu, Rupayan; Shtoff, Lyudmila. (2025). Semaglutide-Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury.. Clinical case reports, 13(8), e70783. https://doi.org/10.1002/ccr3.70783